由于频繁复发和难以杀灭癌干细胞的特征，头颈部肿瘤的根除非常困难和具有挑战性。中子捕获治疗（Neutron capture therapy，NCT）作为一种非侵入性的潜在疗法已经成为治疗各类型肿瘤的新兴方法。在这里，我们报道了98.5%富集10B的抗EGFR-Gd10B6纳米颗粒可以将大剂量的每克肿瘤组织中158微克10B和56.8微克157Gd传送，同时具有非常高的肿瘤至血液（T/B）10B比值4.18，并能够通过CT/MRI图像引导发挥很好的GdBNCT联合作用，以杀灭癌干细胞和根除复发的头颈部肿瘤。这导致了81天的长平均半寿期，成为创纪录的结果，并且超过了使用放射治疗和T细胞介导免疫疗法的最佳结果（70天）报告文献中的结果。© 2023 The Authors. 版权所有 American Chemical Society 发表。

Eradication of head-and-neck (H&N) tumors is very difficult and challenging because of the characteristic feature of frequent recurrence and the difficulty in killing cancer stem cells. Neutron capture therapy (NCT) is emerging as a noninvasive potential modality for treatments of various types of tumors. Herein, we report that 98.5% 10B-enriched anti-EGFR-Gd10B6 nanoparticles can not only deliver large doses of 158 μg 10B/g tumor tissues as well as 56.8 μg 157Gd/g tumor tissues with a very high tumor-to-blood (T/B) 10B ratio of 4.18, but also exert very effective CT/MRI image-guided combined GdBNCT effects on killing cancer stem cells and eradication of recurrent head-and-neck (H&N) tumors. This leads to a long average half-lifespan of 81 days for H&N tumor-bearing mice, which is a record-making result, and surpasses the best result reported in the literature using combined radiotherapy and T cell-mediated immunotherapy (70 d).© 2023 The Authors. Published by American Chemical Society.